Dual Deep Learning Approach for Non-invasive Renal Tumour Subtyping with VERDICT-MRI

This work aims to characterise renal tumour microstructure using diffusion MRI (dMRI); via the Vascular, Extracellular and Restricted Diffusion for Cytometry in Tumours (VERDICT)-MRI framework with self-supervised learning. Comprehensive datasets were acquired from 14 patients with 15 biopsy-confirmed renal tumours, with nine b-values in the range b=[0,2500]s/mm2. A three-compartment VERDICT model for renal tumours was fitted to the dMRI data using a self-supervised deep neural network, and ROIs were drawn by an experienced uroradiologist. An economical acquisition protocol for future studies with larger patient cohorts was optimised using a recursive feature selection approach. The VERDICT model described the diffusion data in renal tumours more accurately than IVIM or ADC. Combined with self-supervised deep learning, VERDICT identified significant differences in the intracellular volume fraction between cancerous and normal tissue, and in the vascular volume fraction between vascular and non-vascular. The feature selector yields a 4 b-value acquisition of b = [70,150,1000,2000], with a duration of 14 minutes.

ssVERDICT: Self-Supervised VERDICT-MRI for Enhanced Prostate Tumour Characterisation

Purpose: Demonstrating and assessing self-supervised machine learning fitting of the VERDICT (Vascular, Extracellular and Restricted DIffusion for Cytometry in Tumours) model for prostate. Methods: We derive a self-supervised neural network for fitting VERDICT (ssVERDICT) that estimates parameter maps without training data. We compare the performance of ssVERDICT to two established baseline methods for fitting diffusion MRI models: conventional nonlinear least squares (NLLS) and supervised deep learning. We do this quantitatively on simulated data, by comparing the Pearson's correlation coefficient, mean-squared error (MSE), bias, and variance with respect to the simulated ground truth. We also calculate in vivo parameter maps on a cohort of 20 prostate cancer patients and compare the methods' performance in discriminating benign from cancerous tissue via Wilcoxon's signed-rank test. Results: In simulations, ssVERDICT outperforms the baseline methods (NLLS and supervised DL) in estimating all the parameters from the VERDICT prostate model in terms of Pearson's correlation coefficient, bias, and MSE. In vivo, ssVERDICT shows stronger lesion conspicuity across all parameter maps, and improves discrimination between benign and cancerous tissue over the baseline methods. Conclusion: ssVERDICT significantly outperforms state-of-the-art methods for VERDICT model fitting, and shows for the first time, fitting of a complex three-compartment biophysical model with machine learning without the requirement of explicit training labels.